EUVIMEDEUVIMED entdecken
Crossref

Analysis of risk factors for patients with cesarean scar pregnancy treated with methotrexate combined with suction curettage

Lin Mu iD, Huifang Weng, Yan Dong

Archives of Gynecology and Obstetrics · 02.05.2023 · 308 (3) · 913-918

DOI: 10.1007/s00404-023-07049-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 02.05.2023. Verfasst von Lin Mu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Zhejiang Province, Hangzhou, Chin…. Hauptthemen laut MEDLINE: Methotrexate, Pregnancy, Ectopic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Zhejiang Province Public Welfare Technology Application Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To analyze the predictive value of clinical and ultrasound parameters for treatment failure after administration of methotrexate (MTX) in combination with suction curettage (SC) in treatment of cesarean scar pregnancy (CSP) in the early first trimester. METHODS: In this retrospective cohort study, electronic medical records of patients diagnosed with CSP and initially treated between 2015 and 2022 with MTX combined with SC were reviewed and outcome data were collected. RESULTS: 127 patients met inclusion criteria. 25 (19.69%) required additional treatment. Logistic regression analysis indicated that factors independently associated with the need for additional treatment included progesterone level > 25 mIU/mL (OR: 1.97; 95% CI: 0.98-2.87, P = 0.039), abundant blood flow (OR: 5.19; 95% CI: 2.44-16.31, P = 0.011), gestational sac size > 3 cm (OR: 2.54; 95% CI: 1.12-6.87, P = 0.029), and the myometrial thickness between the bladder and gestational sac < 2.5 mm (OR: 3.48; 95% CI: 1.91-6.98, P = 0.015). CONCLUSIONS: Our study identified several factors which increase the need for additional treatment following the initial treatment of CSP with MTX and SC. Alternative therapy should be considered if these factors are present.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexatePregnancy, EctopicPregnancyFemaleHumansVacuum CurettageCicatrixRetrospective StudiesCesarean SectionCurettageRisk FactorsTreatment Outcome

Stichwörter der Autor:innen

Cesarean scar pregnancyHigh-intensity focused ultrasoundMethotrexateSuction curettageUterine artery embolization

Substanzen

Methotrexate

Autor:innen und Institutionen

  • Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Zhejiang Province, Hangzhou, China. 2308019@zju.edu.cn.
  • Department of Ultrasound, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Province, Hangzhou, China.
  • Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Zhejiang Province, Hangzhou, China.

ORCID-Profile: Lin Mu

Förderung

  • Zhejiang Province Public Welfare Technology Application Research Project

Zitieren

APA

Mu, L., Weng, H., & Dong, Y. (2023). Analysis of risk factors for patients with cesarean scar pregnancy treated with methotrexate combined with suction curettage. Archives of Gynecology and Obstetrics, 308(3), 913-918. https://doi.org/10.1007/s00404-023-07049-x

Vancouver

Mu L, Weng H, Dong Y. Analysis of risk factors for patients with cesarean scar pregnancy treated with methotrexate combined with suction curettage. Archives of Gynecology and Obstetrics. 2023;308(3):913-918. doi:10.1007/s00404-023-07049-x

BibTeX
@article{Mu2023,
  author = {Mu, Lin and Weng, Huifang and Dong, Yan},
  title = {Analysis of risk factors for patients with cesarean scar pregnancy treated with methotrexate combined with suction curettage},
  journal = {Archives of Gynecology and Obstetrics},
  year = {2023},
  volume = {308},
  number = {3},
  pages = {913--918},
  doi = {10.1007/s00404-023-07049-x}
}
Kostenlos starten →